

Strategic Partnership with Roivant Sciences

December, 2020



SK holdings' Bio Financial Story

SK holdings seeks to enhance our enterprise value by i) growing *SK biopharm* and *SK pharmteco* while ii) securing next growth engines to accelerate growth momentum

Strategic Agendas

- 1** ***SK biopharm* (KOSPI IPO in JUL, '20) has been solidifying its global leadership, utilizing established R&D capabilities and sales & marketing networks especially in CNS**
 - Differentiated success story: The first in Korea to launch two US FDA approved drugs in CNS
 - CNS, the second largest market following Oncology, is expected to reach \$144B by 2025 (CAGR 8%)
- 2** ***SK pharmteco* has secured a strong global presence in the chemical CMO market with integrated operation of facilities in strategic locations** (acquisitions of BMS's facilities in Europe and AFC in the US); while **exploring expansion opportunities** (e.g. biologics)
 - Strong global competitiveness in small molecule API → strongly positioned to join the ranks of global top 15 CMO players
- 3** **Securing next growth engines to accelerate growth momentum → enhancing SK holdings' enterprise value and attracting investors**
 - Seeking to develop SK's own unique, differentiated investment strategy in new drug development

SK holdings' Bio Expansion: Next Momentum


[Areas of Focus]

Utilize resources raised from SK biopharm's IPO


- ❑ Focus on "growth" market over "mature" market
 - Do not compete with Big Pharm (no money-pouring race)
 - Reflecting the market trend of "impact & growth investing," rather than seeking short-term returns
- ❑ Areas where SK has a global leading potential
- ❑ Disruptive tech. capable of bringing BM innovation to the traditional drug dev. process
- ❑ Areas where synergy is possible w/ SK's bio portfolio (e.g. SK Biopharm, SK Pharmteco etc.)

[How?]

- ❑ Developing "Multi-Platform" backed by promising technologies by utilizing SK's investment capabilities
- ❑ "Flexible & Open Investment Play" to mitigate drug dev. risk and accelerate dev. process
 - JVs, minor/major equity investment, consolidation etc.



Roivant Sciences



Mission

- **Bringing innovation to drug dev. biz.**
"Improve the delivery of healthcare to patients by treating every inefficiency as an opportunity"
- **Addressing the industry's deep-rooted pain point** (time & cost) **with an end-to-end AI platform**

Vants

- **18 Vants**
14 in disease areas and 4 in AI/DT
 - 4 Listed Vants: AXO(2015), MYO(2016), URO(2018), and IMM(2020)
- **20 pipelines** (Phase III: II:I = 4:14:2)

Founder

- **Vivek Ramaswamy**
 - AB in Biology (Harvard), JD (Yale)
 - Former biotech hedge fund manager

Funding

- **Raised equity funding of \$1.1B from the Softbank Vision Fund in 2017**
- **Secured funds for new drug dev. through IPO and JVs**
 - Sold equities of five Vants (\$3B, '19)

1. MYOVANT, ENZYVANT, SPIROVANT, UROVANT, ALTAVANT and 11% equity stake in Roivant Sciences

Bringing a fresh perspective to BM

Pharma Industry

- ❑ Many candidates are shelved or deprioritized for non-scientific reasons



Solution

- ❑ Developing system conducive to an accelerated clinical dev. process → *Faster to get clinical results, thus improving efficiency in R&D*
- ❑ Parent Company + Subsidiary Companies → *Minimize investment risk*

Roivant (Parent Co.)

- Incubation/Support
- Initial investment

Vants (Subsidiary Co.)

- Clinical trials/ Development
- Financing

- ❑ **Securing pipeline through win-win partnerships**

- Re-evaluate pipeline from the ROI perspective

- ❑ **World-class team building**

- Attract top talent by setting a clear vision for each Vant (each Vant is designated to a particular therapeutic area of focus) and developing a strong incentive system

- ❑ **Clinical/Development-centered operation**

- Milestone-based decision-making

- ❑ **Relentless pursuit of innovation for accelerated clinical trials and development**

※ Myovant: Founded in April, 2016; NASDAQ IPO in October, 2016; Initiated P3 trials in January, 2017; Submitted NDA in April, 2020


What is Targeted Protein Degradation?

A new therapeutic approach that works by degrading disease-causing proteins, thus overcoming the limitations of conventional protein inhibition-based drug discovery

Protein Degradation

❑ Degrading disease-causing proteins using the UPS (Ubiquitin-Proteasome System)

- Protein degraders consist of i) Binder that binds to a target protein ii) Ligand engaging E3 Ligase; and iii) Linker



- ❑ **The concept was first proposed by Prof. Crews in 2001; First PoC in animals in 2015; succeeded in P1 in 2020**

“Disruptive technology with improved efficacy that promises to overcome traditional drug dev. limitations”

Competitive Advantages

- 1 Potential to target historically “undruggable” proteins** (about 80% of disease-related proteins)
- 2 Relapse, which is common with traditional inhibitors, could be resolved**
 - Overcoming drug resistance resulting from mutations
- 3 Combining advantages of both small molecules and biologics**

Comparison	Small molecule	Antibody	Degrader
Cellular permeability	O	X	O
Oral bioavailability	O	X	O
Safety	Low	O	O
Degrade targeted protein	X	X	O
Target accessibility	>15%	>20%	100%

Protein Degradator Market Trend

Relatively a new emerging market with Arvinas, Kymera and C4 leading the way

- ① **The first generation of biotech companies founded by opinion leaders are leading the market**
Despite being in pre-clinical stage, successfully have debuted on the NASDAQ in a row since July 2020
- ② **Big Pharma makes multi-trillion dollar co-investments to secure protein degradation-related technologies**

Company	Founding Year	IPO	Market Cap*	Degradator Pipeline	Partnership	Remarks
Arvinas	2013	Sep.,2018	\$1.0B	Phase 1 AR, ER	② Genentech(\$650M), Bayer(\$750M), Pfizer(\$830M), Merck(\$434M)	Founded by Yale Professor C. Crews
Kymera	2017	① Aug.,2020	\$2.1B	Pre-Clinical IRAK4, STAT3	GSK(Unkn.), Vertex(\$1B), Sanofi(\$2B)	VC -backed/ Co-investment by Lilly and Amgen
C4	2016	Oct.,2020	\$1.3B	Pre-Clinical IKZF1/3, BRD9	Roche(\$750M), Calico(Unkn.), Biogen(\$415M)	Founded by Harvard Professor J. Bradner
Nurix	2009	July,2020	\$1.7B	Pre-Clinical BTK, CBL-B	Celgene(\$455+M), Gilead(\$2.48B), Sanofi(\$2.5B)	Shifted R&D focus to PROTAC


As of December 3, 2020*

Strategic Investment

**Strategic investment in the “3 Tool Company” w/ ① Global top-tier technology
② AI capabilities and ③ Scalability in clinical development**

❑ Roivant develops “Protein Degradation Platform”

- ① Acquired *U-M Oncopria Therapeutics* equipped with strong protein degrader technologies
- ② Developing AI engine for degraders, utilizing “VantAI,” Roivant’s computational drug discovery platform
- ③ Optimizing the pre-clinical/clinical process



Pipeline

▪ **Rich pipeline consisting of first & best-in-class protein degrader candidates**

- A leading candidate to be advanced to clinical in 2021

Technology

▪ **AI Platform being developed across the whole degrader development process in cooperation with VantAI** (under development for 6 targets)

Capabilities

▪ **Close collaboration b/w Oncopria** (Degradation R&D), **Roivant** (Clinical Development) **and VantAI** (AI) **to secure core capabilities in a short period of time**

Social Value


- **Degrading disease-causing proteins to improve efficacy → improved efficacy to more patients**
- **Utilizing AI to address drug dev. inefficiency**

Strategic Investment

SK holdings' strategic investment in the "Targeted Protein Degradator" area will strengthen SK's Bio portfolio as well as enhance the enterprise value

"Become a leading platform company* by 2025"

*Regeneron (antibody engineering), Ionis (gene therapy) etc



□ **Growing as SK's major Bio portfolio Co. by continuing to expand pipeline w/ promising technology platform**

- Securing next-generation degrader technologies to strengthen the leadership position
- Expecting to build multiple Vants around new drug candidates from the targeted protein degradation platform over time

